Endotoxin Adsorbent Therapy in Severe COVID-19 Pneumonia
© 2021 S. Karger AG, Basel..
INTRODUCTION: Uncontrolled systemic inflammation may occur in severe coronavirus disease 19 (COVID-19). We have previously shown that endotoxemia, presumably from the gut, may complicate COVID-19. However, the role of endotoxin adsorbent (EA) therapy to mitigate organ dysfunction in COVID-19 has not been explored.
METHODS: We conducted a retrospective observational study in COVID-19 patients who received EA therapy at the King Chulalongkorn Memorial Hospital, Bangkok, Thailand, between March 13 and April 17, 2020. Relevant clinical and laboratory data were collected by inpatient chart review.
RESULTS: Among 147 hospitalized COVID-19 patients, 6 patients received EA therapy. All of the 6 patients had severe COVID-19 infection with acute respiratory distress syndrome (ARDS). Among these, 5 of them were mechanically ventilated and 4 had complications of secondary bacterial infection. The endotoxin activity assay (EAA) results of pre-EA therapy ranged from 0.47 to 2.79. The choices of EA therapy were at the discretion of attending physicians. One patient was treated with oXiris® along with continuous renal replacement therapy, and the others received polymyxin B hemoperfusion sessions. All patients have survived and were finally free from the mechanical ventilation as well as had improvement in PaO2/FiO2 ratio and decreased EAA level after EA therapy.
CONCLUSIONS: We demonstrated the clinical improvement of severe COVID-19 patients with elevated EAA level upon receiving EA therapy. However, the benefit of EA therapy in COVID-19 ARDS is still unclear and needs to be elucidated with randomized controlled study.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Blood purification - 51(2022), 1 vom: 14., Seite 47-54 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Peerapornratana, Sadudee [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.01.2022 Date Revised 01.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1159/000515628 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324127022 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324127022 | ||
| 003 | DE-627 | ||
| 005 | 20240401231952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1159/000515628 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1359.xml |
| 035 | |a (DE-627)NLM324127022 | ||
| 035 | |a (NLM)33857940 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Peerapornratana, Sadudee |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endotoxin Adsorbent Therapy in Severe COVID-19 Pneumonia |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2022 | ||
| 500 | |a Date Revised 01.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021 S. Karger AG, Basel. | ||
| 520 | |a INTRODUCTION: Uncontrolled systemic inflammation may occur in severe coronavirus disease 19 (COVID-19). We have previously shown that endotoxemia, presumably from the gut, may complicate COVID-19. However, the role of endotoxin adsorbent (EA) therapy to mitigate organ dysfunction in COVID-19 has not been explored | ||
| 520 | |a METHODS: We conducted a retrospective observational study in COVID-19 patients who received EA therapy at the King Chulalongkorn Memorial Hospital, Bangkok, Thailand, between March 13 and April 17, 2020. Relevant clinical and laboratory data were collected by inpatient chart review | ||
| 520 | |a RESULTS: Among 147 hospitalized COVID-19 patients, 6 patients received EA therapy. All of the 6 patients had severe COVID-19 infection with acute respiratory distress syndrome (ARDS). Among these, 5 of them were mechanically ventilated and 4 had complications of secondary bacterial infection. The endotoxin activity assay (EAA) results of pre-EA therapy ranged from 0.47 to 2.79. The choices of EA therapy were at the discretion of attending physicians. One patient was treated with oXiris® along with continuous renal replacement therapy, and the others received polymyxin B hemoperfusion sessions. All patients have survived and were finally free from the mechanical ventilation as well as had improvement in PaO2/FiO2 ratio and decreased EAA level after EA therapy | ||
| 520 | |a CONCLUSIONS: We demonstrated the clinical improvement of severe COVID-19 patients with elevated EAA level upon receiving EA therapy. However, the benefit of EA therapy in COVID-19 ARDS is still unclear and needs to be elucidated with randomized controlled study | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Acute respiratory distress syndrome | |
| 650 | 4 | |a Adsorption therapy | |
| 650 | 4 | |a Coronavirus disease 19 | |
| 650 | 4 | |a Critical care | |
| 650 | 4 | |a Endotoxemia | |
| 650 | 4 | |a Endotoxin adsorbent | |
| 650 | 7 | |a Membranes, Artificial |2 NLM | |
| 650 | 7 | |a Heparin |2 NLM | |
| 650 | 7 | |a 9005-49-6 |2 NLM | |
| 650 | 7 | |a Polymyxin B |2 NLM | |
| 650 | 7 | |a J2VZ07J96K |2 NLM | |
| 700 | 1 | |a Sirivongrangson, Phatadon |e verfasserin |4 aut | |
| 700 | 1 | |a Tungsanga, Somkanya |e verfasserin |4 aut | |
| 700 | 1 | |a Tiankanon, Kanitha |e verfasserin |4 aut | |
| 700 | 1 | |a Kulvichit, Win |e verfasserin |4 aut | |
| 700 | 1 | |a Putcharoen, Opass |e verfasserin |4 aut | |
| 700 | 1 | |a Kellum, John A |e verfasserin |4 aut | |
| 700 | 1 | |a Srisawat, Nattachai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood purification |d 1993 |g 51(2022), 1 vom: 14., Seite 47-54 |w (DE-627)NLM012656127 |x 1421-9735 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2022 |g number:1 |g day:14 |g pages:47-54 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1159/000515628 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2022 |e 1 |b 14 |h 47-54 | ||